Attenuated pestivirus
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsGregor Meyers, Birke Andrea Tews, Eva-Maria Schuermann
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Erns glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well to a method of attenuating a pestivirus comprising the step of modifying the Erns glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Erns glycoprotein.
Claims25
An immunogenic composition comprising an attenuated pestivirus, wherein the attenuated pestivirus does not produce a dimeric Erns glycoprotein, wherein at least the last cysteine residue of the Erns glycoprotein of the attenuated pestivirus is deleted or substituted by a non-cysteine amino acid residue.
An attenuated pestivirus, wherein the attenuated pestivirus does not produce a dimeric Erns glycoprotein and has at least one mutation in the Npro protein such that the Npro protein is inactivated wherein at least the last cysteine residue of the Erns glycoprotein is deleted or substituted by a non-cysteine amino acid residue.
A recombinant attenuated BVDV, wherein the attenuated BVDV does not produce a dimeric Erns glycoprotein wherein at least the last cysteine residue of the Erns glycoprotein of the attenuated BVDV is deleted or substituted by a non-cysteine amino acid residue.
A method for attenuating a pestivirus, comprising modifying the Erns glycoprotein of the pestivirus such that the attenuated pestivirus does not produce a dimeric Erns glycoprotein wherein at least the last cysteine residue of the Erns glycoprotein of the is deleted or substituted by a non-cysteine amino acid residue.
Dependencies are inferred from the claim text.